Hemogenyx Pharmaceuticals PLC Announces Result of Annual General Meeting
LONDON, ENGLAND / ACCESSWIRE / June 25, 2021 / Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF) (LSE:HEMO) is pleased to announce that, at the Annual General Meeting (‘AGM’) held earlier today, all resolutions were duly passed. The numbers of votes for each resolution are presented below.
AGM Voting Results
|Ordinary Resolutions||Votes for||% of votes cast for||Votes Against||% of votes cast against||Total votes cast||Total votes cast as % of ISC (1)||Votes with-held (2)|
|1. To adopt the 2020 Annual Report and Accounts||126,557,317||99.87%||168,193||0.13%||126,725,510||12.93%||289,150|
|2. To approve the Directors' Remuneration Policy||125,619,330||99.07%||1,177,033||0.93%||126,796,363||12.94%||218,297|
|3. To approve the Directors' Remuneration Report||125,638,477||99.07%||1,177,033||0.93%||126,815,510||12.94%||199,150|
|4. To reappoint the Company's auditor||126,528,170||99.87%||168,193||0.13%||126,696,363||12.93%||318,297|
|5. To authorise the Audit Committee to determine the auditor's remuneration||126,356,107||99.72%||350,256||0.28%||126,706,363||12.93%||308,297|
|6. To re-elect Sir Marc Feldmann as a director of the Company||125,895,121||99.28%||911,242||0.72%||126,806,363||12.94%||208,297|
|7. To authorise the Directors to allot equity securities||125,663,209||99.11%||1,133,154||0.89%||126,796,363||12.94%||218,297|
|Special Resolutions||Votes for||% of votes cast for||Votes against||% of votes cast against||Total votes cast||Total votes cast as % of ISC (1)||Votes with-held (2)|
|8. To disapply pre-emption provisions||123,047,368||97.04%||3,748,995||2.96%||126,796,363||12.94%||218,297|
|9. To adopt new Articles of Association||125,663,209||99.27%||923,154||0.73%||126,586,363||12.92%||428,297|
|10. To adopt new Articles of Association||126,014,268||99.36%||811,242||0.64%||126,825,510||12.94%||189,150|
(1) The Company’s issued share capital (‘ISC’) on 23 June 2021, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 979,749,321 ordinary shares.
(2) A ‘vote withheld’ in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
Hemogenyx Pharmaceuticals plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact firstname.lastname@example.org or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com: